A class of drugs, MDM2 inhibitors, being studied as cancer therapeutics may accidentally damage the protective barriers in the brain and eyes, finds new research in mice.

On July 2, the FDA approved linvoseltamab (Lynozyfic; Regeneron), a B-cell maturation antigen (BCMA ... which he conducted during his time at MD Anderson Cancer Center. He also discusses how the ...

Nui Muriwai and Mereana Pearce share their courages journey battling a rare and aggressive cancer diagnosis with hope and resilience.

LifeScan IP Holdings, LLC, an intellectual property holding company for diabetes care and blood glucose monitoring technology, has filed for Chapter 11 bankruptcy protection in the Southern District ...